Barclays’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-248,815
| Closed | -$13.1M | – | 5308 |
|
|
2020
Q3 | $13.1M | Buy |
248,815
+138,881
| +126% | +$5.75M | 0.01% | 913 |
|
|
2020
Q2 | $3.66M | Buy |
109,934
+3,101
| +3% | +$98.7K | ﹤0.01% | 1614 |
|
|
2020
Q1 | $2.9M | Sell |
106,833
-49,200
| -32% | -$1.37M | ﹤0.01% | 1929 |
|
|
2019
Q4 | $3.08M | Buy |
156,033
+54,645
| +54% | +$874K | ﹤0.01% | 2542 |
|
|
2019
Q3 | $1.31M | Sell |
101,388
-14,119
| -12% | -$170K | ﹤0.01% | 3380 |
|
|
2019
Q2 | $1.44M | Buy |
115,507
+30,853
| +36% | +$410K | ﹤0.01% | 3298 |
|
|
2019
Q1 | $1.23M | Buy |
84,654
+46,155
| +120% | +$590K | ﹤0.01% | 3174 |
|
|
2018
Q4 | $425K | Sell |
38,499
-62,873
| -62% | -$875K | ﹤0.01% | 3949 |
|
|
2018
Q3 | $2.67M | Buy |
101,372
+60,933
| +151% | +$1.65M | ﹤0.01% | 2536 |
|
|
2018
Q2 | $826K | Buy |
40,439
+14,483
| +56% | +$311K | ﹤0.01% | 3480 |
|
|
2018
Q1 | $471K | Buy |
25,956
+7,466
| +40% | +$124K | ﹤0.01% | 4034 |
|
|
2017
Q4 | $258K | Sell |
18,490
-23,347
| -56% | -$316K | ﹤0.01% | 4464 |
|
|
2017
Q3 | $774K | Buy |
41,837
+10,174
| +32% | +$170K | ﹤0.01% | 3231 |
|
|
2017
Q2 | $535K | Buy |
31,663
+16,292
| +106% | +$248K | ﹤0.01% | 3463 |
|
|
2017
Q1 | $206K | Buy |
15,371
+9,504
| +162% | +$149K | ﹤0.01% | 4289 |
|
|
2016
Q4 | $88K | Sell |
5,867
-65
| -1% | -$859 | ﹤0.01% | 4839 |
|
|
2016
Q3 | $69K | Buy |
+5,932
| New | +$69.7K | ﹤0.01% | 4781 |
|
|
2016
Q2 | – | Sell |
-4,731
| Closed | -$48.8K | – | 6774 |
|
|
2016
Q1 | $43K | Buy |
4,731
+2,529
| +115% | +$27.2K | ﹤0.01% | 4864 |
|
|
2015
Q4 | $31K | Sell |
2,202
-17,170
| -89% | -$287K | ﹤0.01% | 5031 |
|
|
2015
Q3 | $310K | Buy |
19,372
+18,142
| +1,475% | +$371K | ﹤0.01% | 3778 |
|
|
2015
Q2 | $26K | Sell |
1,230
-6,296
| -84% | -$125K | ﹤0.01% | 5528 |
|
|
2015
Q1 | $113K | Sell |
7,526
-1,010
| -12% | -$13.1K | ﹤0.01% | 4766 |
|
|
2014
Q4 | $103K | Sell |
8,536
-3,151
| -27% | -$36K | ﹤0.01% | 5184 |
|
|
2014
Q3 | $129K | Sell |
11,687
-4,835
| -29% | -$55.1K | ﹤0.01% | 5129 |
|
|
2014
Q2 | $197K | Buy |
16,522
+1,652
| +11% | +$19.5K | ﹤0.01% | 4829 |
|
|
2014
Q1 | $164K | Sell |
14,870
-8,704
| -37% | -$147K | ﹤0.01% | 4986 |
|
|
2013
Q4 | $400K | Sell |
23,574
-41,508
| -64% | -$697K | ﹤0.01% | 4321 |
|
|
2013
Q3 | $910K | Buy |
65,082
+28,338
| +77% | +$434K | ﹤0.01% | 3459 |
|
|
2013
Q2 | $554K | Buy |
+36,744
| New | +$485K | ﹤0.01% | 4084 |
|
Barclays's MNTA Position: Q4 2020 in Review
Barclays sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 248,815 shares — an estimated $13.1M sold.
Barclays first reported a position in MNTA in Q2 2013 and held it in 29 quarters. The position peaked at $13.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Barclays reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Barclays sold 248,815 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $13.1M.
- Barclays first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Barclays's Momenta Pharmaceuticals, Inc. position peaked at $13.1M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.